Glucocorticoids induce gastroparesis in mice through depletion of L-arginine

Endocrinology (United States)

Volumn 155, Issue 10, 2014, Pages 3899-3908

  Reichardt, Sybille D ^a   Weinhage, Toni ^a,d   Rotte, Anand ^b   Föller, Michael ^b   Oppermann, Martin ^a   Lühder, Fred ^a   Tuckermann, Jan P ^c   Lang, Florian ^b   Van Den Brandt, Jens ^a,e   Reichardt, Holger M ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF ULM   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; ARGINASE 2; ARGININE; DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; MESSENGER RNA; NITRIC OXIDE; UNCLASSIFIED DRUG; ARG2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INDUCTION; FEMALE; GENE MUTATION; INTESTINE CELL; MOUSE; NONHUMAN; PATHOGENESIS; STOMACH ACID SECRETION; STOMACH DISEASE; STOMACH ENLARGEMENT; STOMACH MOTILITY; STOMACH PARESIS; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CHEMICALLY INDUCED; DEFICIENCY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; TRANSGENIC MOUSE; UPREGULATION;

ANIMALS; ARGINASE; ARGININE; DEXAMETHASONE; FEMALE; GASTROPARESIS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCOCORTICOIDS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; RECEPTORS, GLUCOCORTICOID; UP-REGULATION;

EID: 84907203419     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1246     Document Type: Article

References (40)

1. Baschant U, Tuckermann J. The role of the glucocorticoid receptor in inflammation and immunity. J Steroid Biochem Mol Biol. 2010; 120:69-75.
2. Baschant U, Frappart L, Rauchhaus U, et al. Glucocorticoid therapy of antigen-induced arthritis depends on the dimerized glucocorticoid receptor in T cells. Proc Natl Acad Sci U S A. 2011;108:19317-19322.
3. Kirwan J, Power L. Glucocorticoids: action and new therapeutic insights in rheumatoid arthritis. Curr Opin Rheumatol. 2007;19: 233-237.
4. Ford AC, Bernstein CN, Khan KJ, Abreu MT, Marshall JK, Talley NJ, Moayyedi P. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:590-599.
5. Adcock IM, Caramori G, Kirkham PA. Strategies for improving the efficacy and therapeutic ratio of glucocorticoids. Curr Opin Pharmacol. 2012;12:246-251.
6. Zeiser R, Marks R, Bertz H, Finke J. Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies. Ann Hematol. 2004;83:551-565.
7. Rauch A, Seitz S, Baschant U, et al. Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab. 2010;11:517-531.
8. Watson ML, Baehr LM, Reichardt HM, Tuckermann JP, Bodine SC, Furlow JD. A cell-autonomous role for the glucocorticoid receptor in skeletal muscle atrophy induced by systemic glucocorticoid exposure. Am J Physiol. 2012;302:E1210-E1220.
9. Rose AJ, Herzig S. Metabolic control through glucocorticoid hormones: an update. Mol Cell Endocrinol. 2013;380:65-78.
10. Sandu C, Artunc F, Grahammer F, et al. Role of the serum and glucocorticoid inducible kinase SGK1 in glucocorticoid stimulation of gastric acid secretion. Pflugers Arch. 2007;455:493-503.
11. Schubert ML. Gastric secretion. Curr Opin Gastroenterol. 2008; 24:659-664.
12. Tanihata S, Oda S, Nakai S, Uchiyama T. Antiemetic effect of dexamethasone on cisplatin-induced early and delayed emesis in the pigeon. Eur J Pharmacol. 2004;484:311-321.
13. Wüst S, van den Brandt J, Tischner D, et al. Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis. J Immunol. 2008;180:8434-8443.
14. Tuckermann JP, Kleiman A, Moriggl R, et al. Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact allergy. J Clin Invest. 2007;117:1381-1390.
15. Reichardt HM, Kaestner KH, Tuckermann J, et al. DNA binding of the glucocorticoid receptor is not essential for survival. Cell. 1998; 93:531-541.
16. Presman DM, Ogara MF, Stortz M, et al. Live cell imaging unveils multiple domain requirements for in vivo dimerization of the glucocorticoid receptor. PLoS Biol. 2014;12:e1001813.
17. Hudson WH, Youn C, Ortlund EA. The structural basis of direct glucocorticoid-mediated transrepression. Nat Struct Mol Biol. 2013;20:53-58.
18. Meijsing SH, Pufall MA, So AY, Bates DL, Chen L, Yamamoto KR. DNAbinding site sequence directs glucocorticoid receptor structure and activity. Science. 2009;324:407-410.
19. Frijters R, Fleuren W, Toonen EJ, et al. Prednisolone-induced differential gene expression in mouse liver carrying wild type or a dimerization-defective glucocorticoid receptor. BMC Genomics. 2010;11:359.
20. Jewell CM, Scoltock AB, Hamel BL, Yudt MR, Cidlowski JA. Complex human glucocorticoid receptor dim mutations define glucocorticoid induced apoptotic resistance in bone cells. Mol Endocrinol. 2012;26:244-256.
21. Schweingruber N, Fischer HJ, Fischer L, et al. Chemokine-mediated redirection of T cells constitutes a critical mechanism of glucocorticoid therapy in autoimmune CNS responses. Acta Neuropathol. 2014;127:713-729.
22. Reichardt SD, Föller M, Rexhepaj R, et al. Glucocorticoids enhance intestinal glucose uptake via the dimerized glucocorticoid receptor in enterocytes. Endocrinology. 2012;153:1783-1794.
23. Schweingruber N, Haine A, Tiede K, et al. Liposomal encapsulation of glucocorticoids alters their mode of action in the treatment of experimental autoimmune encephalomyelitis. J Immunol. 2011; 187:4310-4318.
24. Usher MG, Duan SZ, Ivaschenko CY, et al. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest. 2010;120: 3350-3364.
25. Martínez V, Cuttitta F, Taché Y. Central action of adrenomedullin to inhibit gastric emptying in rats. Endocrinology. 1997;138:3749-3755.
26. Waisbren SJ, Geibel J, Boron WF, Modlin IM. Luminal perfusion of isolated gastric glands. Am J Physiol. 1994;266:C1013-C1027.
27. Pasham V, Rotte A, Bhandaru M, et al. Regulation of gastric acid secretion by the serum and glucocorticoid inducible kinase isoform SGK3. J Gastroenterol. 2011;46:305-317.
28. Varga G, Ehrchen J, Tsianakas A, et al. Glucocorticoids induce an activated, anti-inflammatory monocyte subset in mice that resembles myeloid-derived suppressor cells. J Leukoc Biol. 2008;84:644-650.
29. Mashimo H, Kjellin A, Goyal RK. Gastric stasis in neuronal nitric oxide synthase-deficient knockout mice. Gastroenterology. 2000; 119:766-773.
30. De Bosscher K, Haegeman G, Elewaut D. Targeting inflammation using selective glucocorticoid receptor modulators. CurrOpinPharmacol. 2010;10:497-504.
31. Jonat C, Rahmsdorf HJ, Park KK, et al. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell. 1990;62:1189-1204.
32. De Bosscher K, Vanden BergheW,Beck IM, et al.Afully dissociated compound of plant origin for inflammatory gene repression. Proc Natl Acad Sci U S A. 2005;102:15827-15832.
33. Schäcke H, Schottelius A, Döcke WD, et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci U S A. 2004;101:227-232.
34. van Lierop MJ, Alkema W, Laskewitz AJ, et al. Org 214007-0: a novel non-steroidal selective glucocorticoid receptor modulator with full anti-inflammatory properties and improved therapeutic index. PLoS ONE. 2012;7:e48385.
35. Vera G, Castillo M, Cabezos PA, et al. Enteric neuropathy evoked by repeated cisplatin in the rat. Neurogastroenterol Motil. 2011; 23:370-378, e162-e373.
36. Wafai L, Taher M, Jovanovska V, Bornstein JC, Dass CR, Nurgali K. Effects of oxaliplatin on mouse myenteric neurons and colonic motility. Front Neurosci. 2013;7:30.
37. Gershon MD. Nerves, reflexes, and the enteric nervous system: pathogenesis of the irritable bowel syndrome. J Clin Gastroenterol. 2005;39:S184-193.
38. Jung M, Hotter G, Viñas JL, Sola A. Cisplatin upregulates mitochondrial nitric oxide synthase and peroxynitrite formation to promote renal injury. Toxicol Appl Pharmacol. 2009;234:236-246.
39. Mihara Y, Egashira N, Sada H, et al. Involvement of spinal NR2Bcontaining NMDA receptors in oxaliplatin-induced mechanical allodynia in rats. Mol Pain. 2011;7:8.
40. Takeda N, Hasegawa S, Morita M, Matsunaga T. Pica in rats is analogous to emesis: an animal model in emesis research. Pharmacol Biochem Behav. 1993;45:817-821.